From Mechanisms to Therapies: Current Advances and Breakthroughs in Alopecia Areata Immunopathology

    September 2025 in “ Frontiers in Immunology
    Huaibo Zhao, Yanan Zhang, Qiang Yan … Xi Chen
    Studysummary This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 115

    1. Complete Hair Regrowth in a Patient With Severe Alopecia Areata Treated With Deucravacitinib Clinical and Experimental Dermatology · 2025
    2. Significant Efficacy of Tofacitinib from China in the Treatment of Alopecia Areata: A Case Report Frontiers in Immunology · 2025
    3. Real-World Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients Acta Dermato Venereologica · 2025
    4. Efficacy and Safety of Tofacitinib in Patients With Total and Universal Alopecia: A Retrospective Evaluation of 69 Patients Indian Journal of Dermatology Venereology and Leprology · 2025
    5. A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo Evaluation Drug Development Research · 2025
    6. Efficacy And Safety Of Ritlecitinib In Asian Patients With Alopecia Areata: A Subgroup Analysis Of The ALLEGRO Phase 2b/3 Trial The Journal of Dermatology · 2025
    7. IKZF1 and Ikaros Overexpression Results in Alopecia Areata-Like Phenotype in Mice Experimental Dermatology · 2025
    8. Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 2021 PubMed · 2025
    9. The Involvement of RIPK1 in Alopecia Areata International Journal of Molecular Sciences · 2025
    10. Efficacy, Safety, and Tolerability of Drugs for Alopecia: A Comprehensive Review Expert Opinion on Drug Metabolism & Toxicology · 2025
    11. Exploring the Effect of Hsa-miR-19b-3p on IL-1R1 Expression and Serum Levels in Alopecia Areata Archives of Dermatological Research · 2025
    12. Fractional CO2 Laser and Minoxidil in the Treatment of Alopecia Areata: A Comparative Study Lasers in Surgery and Medicine · 2025
    13. Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study Journal of Dermatological Treatment · 2025
    14. Comparing the Efficacy of Oral Apremilast, Intralesional Corticosteroids, and Their Combination in Patients With Patchy Alopecia Areata: A Randomized Clinical Controlled Trial Archives of Dermatological Research · 2024
    15. Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study Journal of Cosmetic Dermatology · 2024
    16. Humanized CXCL12 Antibody Delays Onset and Modulates Immune Response in Alopecia Areata Mice: Insights from Single-Cell RNA Sequencing Frontiers in Immunology · 2024
    17. Sustained Hair Regrowth With Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Trial Journal of the American Academy of Dermatology · 2024
    18. Alopecia Areata Exhibits Cutaneous And Systemic OX40 Activation Across Atopic Backgrounds Allergy · 2024
    19. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    20. Comparison of Efficacy and Safety of Tofacitinib and Azathioprine in Patients with Alopecia Areata and Variants: A Double-Blind, Randomized Controlled Trial Archives of Dermatological Research · 2024
    21. Dupilumab for the Treatment of Alopecia Areata in Pediatric Patients with Atopic Dermatitis: A Scoping Review Pediatric Dermatology · 2024
    22. Real-World Effectiveness and Safety of Tofacitinib for Alopecia Areata: A Retrospective Cohort Study of 202 Patients Australasian Journal of Dermatology · 2024
    23. Type-2 Immunity Associated With Type-1 Related Skin Inflammatory Diseases: Friend Or Foe? Frontiers in Immunology · 2024
    24. Deciphering the Complex Immunopathogenesis of Alopecia Areata International Journal of Molecular Sciences · 2024
    25. Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients Journal of cosmetic dermatology · 2024
    26. Interleukin-15 Is a Hair Follicle Immune Privilege Guardian Journal of Autoimmunity · 2024
    27. Efficacy and Safety of Topical Corticosteroid Treatment Under Occlusion for Severe Alopecia Areata in Children: A Single-Center Retrospective Analysis Clinical and experimental dermatology · 2024
    28. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    29. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    30. Treatment of Moderate-to-Severe Alopecia Areata in Patients Over the Age of 65 With Baricitinib Clinical and Experimental Dermatology · 2024
    31. Tralokinumab as a Therapeutic Option for Patients with Concurrent Atopic Dermatitis and Alopecia Areata International Journal of Dermatology · 2024
    32. Deciphering the Molecular Mechanisms of Stem Cell Dynamics in Hair Follicle Regeneration 2024
    33. Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study Acta dermato-venereologica · 2023
    34. Effectiveness of Oral Tofacitinib Treatment on Patients With Moderate-to-Severe Alopecia Areata in Iran Journal of Cosmetic Dermatology · 2023
    35. Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions Frontiers in immunology · 2023
    36. Alopecia Areata: What's New in the Epidemiology, Comorbidities, and Pathogenesis? Journal of Dermatological Science · 2023
    37. Advances In The Mechanism And New Therapies Of Alopecia Areata International journal of rheumatic diseases · 2023
    38. Effectiveness of Tofacitinib in Pre-Adolescent Alopecia Areata: A Retrospective Case Series and Literature Review Acta dermato-venereologica · 2023
    39. Alopecia Areata: Current Treatments and New Directions American Journal of Clinical Dermatology · 2023
    40. Ritlecitinib: First Approval Drugs · 2023
    41. Successful Treatment of Alopecia Universalis With Abrocitinib: A Case Report Journal of Dermatological Treatment · 2023
    42. Comorbid Conditions Associated With Alopecia Areata: A Systematic Review and Meta-Analysis American Journal of Clinical Dermatology · 2023
    43. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    44. Functional Interrogation of Lymphocyte Subsets in Alopecia Areata Using Single-Cell RNA Sequencing Proceedings of the National Academy of Sciences · 2023
    45. Review of Superficial Cryotherapy for the Treatment of Alopecia Areata Journal of Drugs in Dermatology · 2023
    46. Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib Journal of cosmetic dermatology · 2023
    47. Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review Indian journal of dermatology, venereology, and leprology · 2023
    48. The Crosstalk Between PTEN-Induced Kinase 1-Mediated Mitophagy and the Inflammasome in the Pathogenesis of Alopecia Areata Experimental Dermatology · 2023
    49. SIRT1 Downregulation Provokes Immune-Inflammatory Responses in Hair Follicle Outer Root Sheath Cells and May Contribute to Development of Alopecia Areata Journal of Dermatological Science · 2023
    50. Interleukin-15 and Tumor Necrosis Factor-Alpha in Iraqi Patients with Alopecia Areata Dermatology Research and Practice · 2023
    51. The Potential of Regulatory T Cell-Based Therapies for Alopecia Areata Frontiers in Immunology · 2023
    52. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    53. Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review Acta Dermato Venereologica · 2023
    54. Involvement of ILC1-Like Innate Lymphocytes in Human Autoimmunity: Lessons from Alopecia Areata eLife · 2023
    55. Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study Journal of the American Academy of Dermatology · 2023
    56. Effect of Fractional Laser Alone or in Combination on Alopecia Areata: A Systematic Review and Meta-Analysis Journal of cosmetic dermatology · 2023
    57. Rapid Hair Regrowth in an Alopecia Universalis Patient With Deucravacitinib: A Case Report SAGE open medical case reports · 2023
    58. Janus Kinase Inhibitors in the Treatment of Alopecia Areata Prague Medical Report · 2023
    59. Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2022
    60. Scalp Biomarkers During Dupilumab Treatment Support Th2 Pathway Pathogenicity in Alopecia Areata Allergy · 2022
    61. AIRE Deficiency Leads to the Development of Alopecia Areata-Like Lesions in Mice ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2022
    62. Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice Frontiers in immunology · 2022
    63. Dupilumab for Alopecia Areata Treatment: A Double-Edged Sword? Journal of cosmetic dermatology · 2022
    64. Immune-Mediated Alopecias and Their Mechanobiological Aspects Cells and Development · 2022
    65. Lifestyle Factors Involved in the Pathogenesis of Alopecia Areata International journal of molecular sciences · 2022
    66. Alopecia Areata: Current Understanding and Management Journal der Deutschen Dermatologischen Gesellschaft · 2022
    67. The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications Cells · 2021
    68. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    69. Alopecia Areata and Tofacitinib: A Prospective Multicenter Study from a Saudi Population International Journal of Dermatology · 2021
    70. Resident Human Dermal Gamma Delta T-Cells Operate as Stress Sentinels: Lessons from the Hair Follicle Journal of Autoimmunity · 2021
    71. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    72. Alopecia Areata: An Autoimmune Disease of Multiple Players ImmunoTargets and therapy · 2021
    73. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    74. Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update Drug design, development and therapy · 2021
    75. Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options Clinical and Experimental Medicine · 2021
    76. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside Frontiers in immunology · 2020
    77. Pro-Inflammatory Vδ1+ T-Cells Infiltrates Are Present In And Around The Hair Bulbs Of Non-Lesional And Lesional Alopecia Areata Hair Follicles Journal of Dermatological Science · 2020
    78. Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing Its Impact on T Regulatory Cell and NK Cell Populations ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2020
    79. Utility of Azathioprine, Methotrexate, and Cyclosporine as Steroid-Sparing Agents in Chronic Alopecia Areata: A Retrospective Study of Continuation Rates in 138 Patients JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2020
    80. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    81. Treatment of Chronic Alopecia Areata With Tildrakizumab: An Open-Label Pilot Study International Journal of Dermatology · 2020
    82. Immune Cell Regulation of the Hair Cycle Experimental Dermatology · 2020
    83. IL-12/IL-23 Neutralization Is Ineffective for Alopecia Areata in Mice and Humans ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2019
    84. Frontiers in Alopecia Areata Pathobiology Research ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2019
    85. Combination of Photodynamic Therapy with 5-Aminolaevulinic Acid and Microneedling in the Treatment of Alopecia Areata Resistant to Conventional Therapies: Our Experience with 41 Patients Clinical and Experimental Dermatology · 2019
    86. Alopecia Areata Patients Show Deficiency of FOXP3+CD39+ T Regulatory Cells and Clonotypic Restriction of Treg TCRβ-Chain, Highlighting the Immunopathological Aspect of the Disease PloS one · 2019
    87. Treatment of Chronic Extensive Alopecia Areata by Diphenylcyclopropenone Alone Versus in Combination with Anthralin Dermatologic therapy · 2019
    88. Apremilast Is Efficacious in Refractory Alopecia Areata Journal of dermatological treatment · 2019
    89. Pathomechanisms of Immune-Mediated Alopecia International Immunology · 2019
    90. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    91. A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata Archives of dermatological research · 2018
    92. Response to Ustekinumab in Three Pediatric Patients with Alopecia Areata Pediatric dermatology · 2018
    93. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    94. Alopecia Areata: A Review of Disease Pathogenesis British journal of dermatology/British journal of dermatology, Supplement · 2018
    95. iNKT Cells Ameliorate Human Autoimmunity: Lessons from Alopecia Areata Journal of autoimmunity · 2018
    96. IL-17 Inhibition: Is It the Long-Awaited Savior for Alopecia Areata? Archives of Dermatological Research · 2018
    97. Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2017
    98. Regulatory T Cells in Skin: Role of Foxp3+ CD4+ Tregs in Skin Homeostasis and Immune Tolerance Immunology · 2017
    99. The Contributory Roles of Th17 Lymphocyte and Cytotoxic T Lymphocyte at the Hair Bulge Region and Hair Bulb Area in Chronic Alopecia Areata Patients Annals of dermatology/Annals of Dermatology · 2017
    100. Increased Blood Levels of NKG2D+CD4+ T Cells in Patients with Alopecia Areata Journal of the American Academy of Dermatology · 2016
    101. A Review on Laser and Light-Based Therapies for Alopecia Areata Journal of Cosmetic and Laser Therapy · 2016
    102. Efficacy and Safety of Superficial Cryotherapy for Alopecia Areata: A Retrospective Comprehensive Review of 353 Cases Over 22 Years The Journal of Dermatology · 2016
    103. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    104. CXCR3 Blockade Inhibits T Cell Migration Into the Skin and Prevents Development of Alopecia Areata Journal of Immunology · 2016
    105. Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies Autoimmunity reviews · 2016
    106. Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism The Journal of Allergy and Clinical Immunology · 2015
    107. Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2015
    108. Assessment of Tissue Levels of Dickkopf-1 in Androgenetic Alopecia and Alopecia Areata Journal of Cosmetic Dermatology · 2015
    109. Imbalance of T-Helper 17 and Regulatory T Cells in Patients with Alopecia Areata The Journal of Dermatology · 2015
    110. Plasmacytoid Dendritic Cells in Alopecia Areata: Missing Link? Journal of the European Academy of Dermatology and Venereology · 2014
    111. The PDE4 Inhibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin In Vivo Journal of Dermatological Science · 2014
    112. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    113. Type 1 Interferon Signature in the Scalp Lesions of Alopecia Areata British Journal of Dermatology · 2010
    114. Alefacept for Severe Alopecia Areata: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial Archives of dermatology · 2009
    115. Changes in Populations of HLA-DR+CD3+ Cells and CD57–CD16+ Cells in Alopecia Areata After Corticosteroid Therapy Dermatology · 1994

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019